COMMUNIQUÉS West-GlobeNewswire

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

30/10/2024 - 13:30

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

30/10/2024 - 13:30

REYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release [...]

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

30/10/2024 - 13:30

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended [...]

Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

30/10/2024 - 13:19

Patients experiencing bloating and gastrointestinal discomfort can now order inFoods ® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s office With a simple, at-home finger-prick blood sample, [...]

A Race Against Blindness Grants $1 Million Supporting Axovia Therapeutics’ Planned Clinical Trial for Bardet-Biedl Syndrome (BBS)

30/10/2024 - 13:01

PHOENIX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- A Race Against Blindness, a nonprofit organization dedicated to funding sight-saving research for children, is pleased to announce a $1 million grant to Axovia Therapeutics to [...]

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

30/10/2024 - 13:00

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic [...]

Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors

30/10/2024 - 13:00

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular weight of NM32 allows to [...]

COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP-106 in Generalized Myasthenia Gravis

30/10/2024 - 13:00

CHICAGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of ﬁrst-in-class, disease-modifying therapies designed to induce antigen-speciﬁc [...]

Inspire Medical Systems, Inc. to Present at UBS Global Healthcare Conference

30/10/2024 - 13:00

MINNEAPOLIS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

30/10/2024 - 13:00

Management will also participate in two upcoming investor healthcare conferences SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision [...]

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

30/10/2024 - 13:00

Nes-Ziona, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Japanese Patent [...]

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

30/10/2024 - 13:00

PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report [...]

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

30/10/2024 - 13:00

PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday [...]

DiagnaMed Advancing the Medical Potential of Hydrogen

30/10/2024 - 13:00

Focusing on novel molecular hydrogen therapies for brain health TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company [...]

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

30/10/2024 - 13:00

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer’s disease patients planned for year-end [...]

Glass House Brands to Host Third Quarter 2024 Conference Call on November 13, 2024

30/10/2024 - 13:00

LONG BEACH, Calif. and TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company” (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest- [...]

Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

30/10/2024 - 13:00

SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating [...]

A Family’s Race To Treat Childhood Blindness: A Race Against Blindness Grants $1 Million to Bardet-Biedl Syndrome Research

30/10/2024 - 13:00

An Arizona Family’s Inspirational Journey Highlighted as Donors Across America Come Together to Fund the Advancement of Potential Life-Changing Therapeutic, Offering Hope to the BBS Community and Families PHOENIX, Oct. [...]

Noema Pharma Announces First Patients Dosed in Phase 2b Study with Gemlapodect (NOE-105), a First-In-Class Investigational Therapy for Tourette Syndrome

30/10/2024 - 13:00

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome BASEL, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG , a clinical-stage neuroscience- [...]